Skip to main content
ARS Home » Northeast Area » Boston, Massachusetts » Jean Mayer Human Nutrition Research Center On Aging » Research » Publications at this Location » Publication #423537
Research Project: Nutrition, Sarcopenia, Physical Function, and Skeletal Muscle Capacity During Aging

Location: Jean Mayer Human Nutrition Research Center On Aging

Title: Looking at frailty and intrinsic capacity through a geroscience lens: The ICFSR & Geroscience Task Force

Author
item DE SOUTO BARRETO, PHILIPE - University Hospital Center Of Toulouse
item ROLLAND, YVES - University Of Toulouse
item FERRUCCI, LUIGI - National Institute On Aging (NIA, NIH)
item ARAI, HIDENORI - National Center For Geriatrics And Gerontology
item BISCHOFF-FERRARI, HEIKE - University Of Zurich
item DUQUE, GUSTAVO - Research Institute Of Mcgill University Health Centre
item FIELDING, ROGER - Jean Mayer Human Nutrition Research Center On Aging At Tufts University
item BEARD, JOHN - Columbia University - New York
item MUSCEDERE, JOHN - Queen'S University - Canada
item SIERRA, FELIPE - Hevolution Foundation
item VELLAS, BRUNO - University Of Toulouse
item LEBRASSEUR, NATHAN - Mayo Clinic

Submitted to: Nature Aging
Publication Type: Review Article
Publication Acceptance Date: 10/25/2023
Publication Date: 11/20/2023
Citation: De Souto Barreto, P., Rolland, Y., Ferrucci, L., Arai, H., Bischoff-Ferrari, H., Duque, G., Fielding, R., Beard, J.R., Muscedere, J., Sierra, F., Vellas, B., Lebrasseur, N.K. 2023. Looking at frailty and intrinsic capacity through a geroscience lens: The ICFSR & Geroscience Task Force. Nature Aging. https://doi.org/10.1038/s43587-023-00531-w.
DOI: https://doi.org/10.1038/s43587-023-00531-w

Interpretive Summary:

Technical Abstract: Intrinsic capacity (IC) and frailty are multidimensional, complementary concepts related to an individual's body functions. IC is operationalized through six functional domains (ie, locomotion, cognition, psychology, vitality/nutrition, vision and hearing) that undergo gradual changes throughout adulthood, whereas frailty is a geriatric syndrome. Despite their relevance for health in aging, the existence of the ICD-11 code "MG2A Ageing associated decline in intrinsic capacity", and the recent development of the geroscience field that proposes that the rate of aging can be modified by interventions with significant effects on health span, no pharmacological approach is currently approved for frailty/IC prevention or treatment. Since IC and frailty are strongly determined by the pace of aging, in keeping with the geroscience paradigm, addressing pharmacologically the pace of aging may be a valid approach to address IC and frailty. To foster the development of IC and frailty clinical trials under a geroscience perspective, the Geroscience Translational Research & International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force met in Toulouse (South West, France) on March 22, 2023. Main recommendations of this Task Force were: 1. Principal Investigators of geroscience trials should systematically present their study design and primary outcome to the FDA and/or EMA for getting their advices; 2. Focus on populations at high risk of functional decline, but still resilient enough to respond to an intervention, such as pre-frail individuals; 3. Operationalize a composite functional endpoint, such as a composite score of IC domains; 4. Stimulate research on biomarkers, particularly markers of stress response/adaptation/resilience, to be included as surrogate efficacy endpoints/secondary endpoints in clinical trials. By focusing on establishing a set of biomarkers representative of the dynamics of the aging process and working closely with drug agencies, Gerotherapeutics trials can pave the way for the personalized and preventive geriatric medicine of the future.